Lexicon Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
12.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.17next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly21.1M
Net Product Sales of INPEFA Quarterly1.1MTarget: Continued commercial growth in heart failure
Cash, Cash Equivalents, and Short-Term Investments Quarterly199.7MTarget: Sufficient runway to support advancement of programs into 2027
Watch Items
- ZYNQUISTA (sotagliflozin) NDA Resubmission for Type 1 DiabetesTrigger: NDA resubmission targeted for mid-2026Action: Monitor FDA acceptance of resubmission and potential regulatory approval in late 2026 based on STENO1 safety data.
- SONATA-HCM Phase 3 Trial EnrollmentTrigger: Enrollment completion of approximately 500 patients targeted for mid-2026Action: Track progress toward the expected topline data readout in Q1 2027.
- LX9851 Phase 1 Obesity Trial ProgressTrigger: Completion of Phase 1 program by Novo Nordisk expected in Q1 2027Action: Monitor potential achievement of a third $10 million milestone payment later in 2026.
- Pilavapadin (LX9211) Phase 3 PartneringTrigger: Phase 3 readiness for diabetic peripheral neuropathic pain (DPNP)Action: Secure a development partner as Lexicon has stated it has no plans to self-fund Phase 3 development.
Research as of 19 Jun 2026